Seattle’s HDT Bio to start U.S. clinical trials of its COVID-19 vaccine candidate

Steve Reed, CEO of HDT Bio. (HDT Bio Photo)An experimental COVID-19 vaccine in development by Seattle-based HDT Bio will enter early-stage clinical trials in the U.S., the company announced yesterday after the U.S. Food and Drug Administration cleared the trial to go forward. The phase 1 trial will enroll 60 volunteers and will assess safety and the strength of the…
« Previous post: | Next post: »